Humulin M3 (30/70) Cartridge (Insulin Human (Rdna))

Humulin M3 (30/70) Cartridge is employed in the treatment of diabetes to provide combined basal and prandial insulin coverage.

• Type 1 diabetes mellitus requiring intensive insulin therapy.
• Type 2 diabetes mellitus when basal and mealtime insulin are indicated.
• Adjunct to diet, exercise and oral antidiabetic agents.
• Situations where a single injection can replace separate basal and rapid‑acting insulin doses.
• Patients transitioning between insulin regimens who need a mixed formulation.
• Use in combination with continuous glucose monitoring to fine‑tune dosing.
• May be selected for patients preferring fewer daily injections.

• Humulin M3 contains recombinant human insulin that binds to the insulin receptor on target cells, activating the intrinsic tyrosine kinase activity of the receptor. This triggers downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane and increasing glucose uptake in muscle and adipose tissue. Simultaneously, hepatic gluconeogenesis and glycogenolysis are suppressed, reducing endogenous glucose production.

Adverse reactions reported with Humulin M3 (30/70) Cartridge vary in frequency and severity.

Common

• Hypoglycemia, presenting as sweating, shakiness, or confusion.
• Redness, swelling, or itching at the injection site.
• Lipohypertrophy or lipoatrophy at repeated injection sites.
• Weight gain associated with improved glycemic control.
• Mild allergic skin reactions such as rash or urticaria.
• Transient nausea or abdominal discomfort.
• Headache or dizziness, especially during dose adjustments.

Serious

• Severe hypoglycemia requiring assistance.
• Anaphylactic or anaphylactoid reactions.
• Persistent edema or heart failure exacerbation.
• Acute hypokalemia.
• Diabetic ketoacidosis if insulin effect is inadequate.
• Severe allergic reaction with angioedema and respiratory distress.
• Unexplained weight loss indicating possible insulin under‑dosing.

When prescribing Humulin M3 (30/70) Cartridge, clinicians and patients should consider several precautions to ensure safe use.

• Assess renal and hepatic function before initiating therapy.
• Adjust dose during periods of illness, stress, or changes in physical activity.
• Monitor blood glucose closely during pregnancy and lactation; insulin requirements may change.
• Use caution in patients with a history of severe hypoglycemia or hypoglycemia unawareness.
• Evaluate for allergic reactions to insulin or excipients before first use.
• Consider cardiovascular status, as rapid changes in glucose can affect heart patients.
• Review concomitant medications that may mask hypoglycemia symptoms.

Humulin M3 (30/70) Cartridge can interact with other medicines, affecting glucose control or increasing risk of adverse events.

Avoid

• Concurrent use of other insulin products without dose adjustment.
• High‑dose beta‑blockers that may mask hypoglycemia symptoms.
• MAO‑A inhibitors that can potentiate insulin’s glucose‑lowering effect.
• Alkylating agents that may cause unpredictable insulin sensitivity.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) may increase hypoglycemia risk.
• Corticosteroids, which raise blood glucose and may require higher insulin doses.
• Thyroid hormones, as hyperthyroidism can enhance insulin clearance.
• Diuretics, especially thiazides, that may affect electrolyte balance and glucose levels.
• ACE inhibitors, which can potentiate insulin’s effect on potassium levels.